Analyzing CARGO Therapeutics (NASDAQ:CRGX) & OKYO Pharma (NASDAQ:OKYO)

OKYO Pharma (NASDAQ:OKYO) and CARGO Therapeutics (NASDAQ:CRGX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Volatility & Risk

OKYO Pharma has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500. Comparatively, CARGO Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500.

Earnings and Valuation

This table compares OKYO Pharma and CARGO Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$16.83 million	N/A	N/A
CARGO Therapeutics	N/A	N/A	-$98.15 million	($4.26)	-0.90

Institutional & Insider Ownership

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 93.2% of CARGO Therapeutics shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by company insiders. Comparatively, 1.4% of CARGO Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations for OKYO Pharma and CARGO Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	0	0	1	0	3.00
CARGO Therapeutics	1	6	0	0	1.86

OKYO Pharma presently has a consensus price target of $7.00, suggesting a potential upside of 493.22%. CARGO Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 292.67%. Given OKYO Pharma’s stronger consensus rating and higher possible upside, equities analysts clearly believe OKYO Pharma is more favorable than CARGO Therapeutics.

Profitability

This table compares OKYO Pharma and CARGO Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
CARGO Therapeutics	N/A	-38.16%	-33.94%

Summary

OKYO Pharma beats CARGO Therapeutics on 7 of the 9 factors compared between the two stocks.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

About CARGO Therapeutics

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.